121 / 1851
The future drug development paradigm?
Histology and molecular
selection
Proof of concept
Safety and tolerability
Substancially efficacy in selected
patients uding innovative trial
designs and endpoints
Functional target selection
Trial design accounting for
interpatient and intratumor
heterogeneity
Pharmacology
Antitumor activity